A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer.

Trial Profile

A Prospective, Open-label, Single Center, Dose Finding Phase I-study With Atu027 (an siRNA Formulation) in Subjects With Advanced Solid Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs ATU 027 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Silence Therapeutics AG
  • Most Recent Events

    • 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Enrolment in the tenth and final dose cohort has been completed and the final treatment is scheduled for 22 June 2012.
    • 06 Jun 2012 Results were reported at the 48th Annual Meeting of the American Society of Clinical Oncology, and in a Silence Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top